Proactive Investors - Run By Investors For Investors

Adial Pharmaceuticals looks to apply its alcohol-use disorder drug to opioid-use disorder

A Phase 2b clinical trial of AD04 showed 'promising results' in treating patients with alcohol-use disorder
Bottle of prescription pills spilled onto the table
The CDC estimates that 72,000 people in the US died of drug overdoses in 2017

Adial Pharmaceuticals Inc (NASDAQ:ADIL) plans to expand the potential of its lead drug AD04, designed to treat alcohol-use disorder, to benefit patients with opioid-use disorder.

A Phase 2b clinical trial of the drug showed “promising results” in treating patients with alcohol use disorder, reducing the frequency and quantity of drinking without any serious adverse effects reported.

Shares more than doubled by Thursday’s closing bell, dipping around 8% to $3.85 in Friday pre-market trading.

READ: Anavex Life Sciences doses patients in Phase 2 ANAVEX2-73 Parkinson disease dementia study

 “We are expanding our activities around AD04 to include opioid use disorder (OUD) and believe this program has significant potential since the physiology and neuro-transmitters involved in opioid addiction are similar to alcohol and could be expected to be modulated by a serotonin-3 receptor antagonist,” said CEO William Stilley in the company’s press statement.

The company is hopeful that AD04 can bring something to the table in an underserved market as the use of opioid and synthetic opioids, such as fentanyl, continue to contribute to overdose deaths in the US.

The Centers for Disease Control estimate that 72,000 people in the US died of drug overdoses in 2017, linking two-thirds of those deaths to opioids.

The clinical-stage biopharmaceutical company focuses on the development of treatments for addictions.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

View full ADIL profile View Profile

Adial Pharmaceuticals Inc Timeline

Related Articles

Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use